Skip to main content

Dosing and Switching Strategies for Paliperidone Palmitate 3-Month Formulation in Patients with Schizophrenia Based on Population Pharmacokinetic Modeling and Simulation, and Clinical Trial Data

Abstract

Paliperidone palmitate 3-month formulation (PP3M), a long-acting injectable atypical antipsychotic, was recently approved in the US and Europe for the treatment of schizophrenia in adult patients who have already been treated with paliperidone palmitate 1-month formulation (PP1M) for ≥4 months. This article reviews the pharmacokinetic rationale for the approved dosing regimens for PP3M, dosing windows, management of missed doses and treatment discontinuation, switching to other formulations, and dosing in special populations. Approved PP3M dosing regimens are based on the comparisons of simulations with predefined dosing regimens using paliperidone palmitate and oral paliperidone extended release (ER) population pharmacokinetic models (one-compartment model with two saturable absorption processes for PP3M; one-compartment model with parallel zero- and first-order absorption for PP1M; two-compartment model with sequential zero- and first-order absorption for ER) versus clinical trial data. Covariates were obtained by resampling subject covariates from the pharmacokinetics database for PP1M and PP3M. Simulation scenarios with varying doses and covariate values were generated. The population median and 90% prediction interval of the simulated concentration-time profiles were plotted for simulation outcomes evaluation. Simulations described in this paper provide (a) simulated plasma exposures for switching from PP1M to PP3M, (b) support for a once-every-3-months injection cycle, (c) information on dosing windows and managing missed doses of PP3M, (d) important guidance on PP3M dosing in special patient populations, and (e) key PP3M pharmacokinetic exposure metrics based on the population pharmacokinetic PP3M model. Population pharmacokinetics provided practical guidance to establish dosing regimens for PP3M.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

References

  1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., text revision [DSM-IV-TR]. Arlington (VA): American Psychiatric Association; 2000.

  2. Andreasen NC. Symptoms, signs, and diagnosis of schizophrenia. Lancet. 1995;346(8973):477–81.

    CAS  Article  PubMed  Google Scholar 

  3. Ascher-Svanum H, Faries DE, Zhu B, Ernst FR, Swartz MS, Swanson JW. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry. 2006;67(3):453–60.

    Article  PubMed  Google Scholar 

  4. Di Pace C, Paletta S, Reggiori A, Maffini M, Chirico M, Mauri MC, Altamura AC. Paliperidone “long-acting” and plasma levels along 1 year of maintenance therapy in schizophrenia and schizoaffective disorder. Eur Neuropsychopharmacol. 2015;S2:525.

    Article  Google Scholar 

  5. US label of INVEGA® SUSTENNA® (Revised 01/2016). Available at: http://www.invegasustenna.com/important-product-information. Accessed 10 May 2016.

  6. EU label of TREVICTA® (last updated on eMC 09/2016). Available at https://www.medicines.org.uk/emc/medicine/32050. Accessed 16 Dec 2016.

  7. Keith SJ, Kane JM. Partial compliance and patient consequences in schizophrenia: our patients can do better. J Clin Psychiatry. 2003;64(11):1308–15.

    Article  PubMed  Google Scholar 

  8. Remenar JF. Making the leap from daily oral dosing to long-acting injectables: lessons from the antipsychotics. Mol Pharm. 2014;11(6):1739–49.

    CAS  Article  PubMed  Google Scholar 

  9. Gopal S, Gassmann-Mayer C, Palumbo J, Samtani MN, Shiwach R, Alphs L. Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia. Curr Med Res Opin. 2010;26(2):377–87.

    CAS  Article  PubMed  Google Scholar 

  10. Ravenstijn P, Remmerie B, Savitz A, De Meulder M, Hough D, Gopal S, et al. Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: a phase-1, single-dose, randomized, open-label study. J Clin Pharmacol. 2016;56(3):330–9.

    CAS  Article  PubMed  Google Scholar 

  11. Berwaerts J, Liu Y, Gopal S, Nuamah I, Xu H, Savitz A, Coppola D, Schotte A, Remmerie B, Maruta N, Hough DW. Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2015;72(8):830–9.

    Article  Google Scholar 

  12. Magnusson MO, Samtani MN, Plan EL, Jonsson EN, Rossenu S, Vermeulen A, et al. Population pharmacokinetic modeling of paliperidone palmitate 3-month formulation poster presented at PAGE 24; 2015. Abstr 3408. http://www.page-meeting.org/?abstract=3408.

  13. Magnusson MO, Samtani MN, Plan EL, Jonsson EN, Rossenu S, Vermeulen A, et al. Population pharmacokinetics of a novel once-every 3 months, intramuscular formulation of paliperidone palmitate in patients with schizophrenia. Clin Pharmacokinet. 2016. [Epub ahead of print].

  14. Samtani MN, Vermeulen A, Stuyckens K. Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychotic. Clin Pharmacokinet. 2009;48(9):585–600.

    CAS  Article  PubMed  Google Scholar 

  15. Pandina G, Lane R, Gopal S, Gassmann-Mayer C, Hough D, Remmerie B, et al. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(1):218–26.

    CAS  Article  PubMed  Google Scholar 

  16. Gopal S, Hough DW, Xu H, Lull JM, Gassmann-Mayer C, Remmerie BM, Eerdekens MH, Brown DW. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study. Int Clin Psychopharmacol. 2010;25(5):247–56.

    Article  PubMed  Google Scholar 

  17. Cirincione B, Redman M, Fiedler-Kelley J, et al. Population pharmacokinetics of paliperidone ER in healthy subjects and patients with schizophrenia [poster no. PI-21]. Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, 21–24 Mar 2007, Anaheim (CA).

  18. Beal SL, Sheiner LB, Boeckmann AJ, Bauer RJ. NONMEM Users Guides. 1989 Icon development solutions, Ellicott City, Maryland.

  19. R Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN: 3-900051-07-0. Available at http://www.R-project.org. Accessed 18 Jan 2016.

  20. Samtani MN, Gopal S, Gassmann-Mayer C, Alphs L, Palumbo JM. Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data. CNS Drugs. 2011;25(10):829–45.

    CAS  PubMed  Google Scholar 

  21. Karlsson P, Dencker E, Nyberg S, More L, More JM. Pharmacokinetics, dopamine D2 and serotonin 5 HT2A receptor occupancy and safety profile of paliperidone ER in healthy subjects. Schizophr Res. 2006;81(Suppl. 1):85–6.

    Google Scholar 

  22. Kapur S, Remington G, Jones C, et al. High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study. Am J Psychiatry. 1996;153:948–50.

    CAS  Article  PubMed  Google Scholar 

  23. Nordstrom AL, Farde L, Wiesel FA, et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry. 1993;33:227–35.

    CAS  Article  PubMed  Google Scholar 

  24. Nyberg S, Nordstrom AL, Halldin C, Farde L. Positron emission tomography studies on D2 dopamine receptor occupancy and plasma antipsychotic drug levels in man. Int Clin Psychopharmacol. 1995;10(Suppl 3):81–5.

    PubMed  Google Scholar 

  25. Vermeir M, Naessens I, Remmerie B, Mannens G, Hendrickx J, Sterkens P, Talluri K, Boom S, Eerdekens M, van Osselaer N, Cleton A. Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans. Drug Metab Dispos. 2008;36(4):769–79.

    CAS  Article  PubMed  Google Scholar 

  26. Boom S, Thyssen A, Crauwels H, et al. The influence of hepatic impairment on the pharmacokinetics of paliperidone. Int J Clin Pharmacol Ther. 2009;47(10):606–16.

    CAS  Article  PubMed  Google Scholar 

  27. Savitz AJ, Xu H, Gopal S, Nuamah I, Ravenstijn P, et al. Efficacy and safety of paliperidone palmitate 3-month formulation for patients with schizophrenia: a randomized, multicenter, double-blind, noninferiority study. Int J Neuropsychopharmacol. 2016; 19(7):1–14. doi:10.1093/ijnp/pyw018.

Download references

Acknowledgements

The authors would like to thank Sebastian Ueckert for his contribution to the simulations and Tinka Tuinstra Ph.D., an employee of AUTHOR!, for her medical writing assistance, both sub-contractors of Pharmetheus.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mats O. Magnusson.

Ethics declarations

Conflict of Interest

M. O. Magnusson, E. L. Plan, and E. N. Jonsson are employees of Pharmetheus and received consultancy fees from Janssen Research & Development. M. N. Samtani, S. Rossenu, A. Vermeulen, and A. Russu are employees of Janssen Research & Development and own Johnson & Johnson stocks and/or stock options.

Funding

S. Ueckert and T. Tuinstra received consultancy fees from Janssen Research & Development for their work on this manuscript.

Additional information

M. O. Magnusson and M. N. Samtani contributed equally to this work.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 924 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Magnusson, M.O., Samtani, M.N., Plan, E.L. et al. Dosing and Switching Strategies for Paliperidone Palmitate 3-Month Formulation in Patients with Schizophrenia Based on Population Pharmacokinetic Modeling and Simulation, and Clinical Trial Data. CNS Drugs 31, 273–288 (2017). https://doi.org/10.1007/s40263-017-0416-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40263-017-0416-1

Keywords

  • Extended Release
  • Paliperidone
  • Population Pharmacokinetic Model
  • Paliperidone Palmitate
  • Mild Renal Impairment